Skip to main content
Erschienen in: Journal of Gastroenterology 9/2019

02.03.2019 | Original Article—Alimentary Tract

Epstein–Barr virus status is a promising biomarker for endoscopic resection in early gastric cancer: proposal of a novel therapeutic strategy

verfasst von: Hiroki Osumi, Hiroshi Kawachi, Toshiyuki Yoshio, Satoshi Ida, Noriko Yamamoto, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiaki Hirasawa, Tomohiro Tsuchida, Naoki Hiki, Kengo Takeuchi, Junko Fujisaki

Erschienen in: Journal of Gastroenterology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Epstein–Barr virus-positive gastric cancer (EBVGC) is associated with a low prevalence of lymph node metastasis (LNM); however, EBV status is not considered in the indication of endoscopic resection (ER). We aimed to clarify the implication of EBV status for ER of pT1b GC.

Methods

Consecutive cases of pT1b GCs treated with surgery between 2005 and 2014 were retrospectively analyzed. Clinicopathological factors and LNM status were compared between EBVGC and non-EBVGC groups.

Results

EBVGC accounted for 7.9% (71 of 898) cases. Compared to non-EBVGC, EBVGC was more frequent in males (p = 0.0055), the upper third region (p < 0.0001), showed elevated growth features (p = 0.0059), and was associated with a lower frequency of accompanying ulceration (p = 0.002), greater depth of submucosal invasion (p = 0.017), and lower frequency of lymphatic invasion (p < 0.0001). Frequency of LNM was significantly lower in EBVGC than in non-EBVGC (4.2% vs. 21.9%, p < 0.0001). In EBVGC, tumors without lymphovascular invasion showed significantly lower frequency of LNM than those with lymphovascular invasion (0 of 50, 0%; vs 3 of 21, 14.3%; p = 0.023). Histologically, 84.5% (60 of 71) of EBVGC included carcinomas with lymphoid stroma and/or lace pattern components.

Conclusions

pT1b EBVGC is a convincing candidate for ER, regardless of risk factors other than lymphovascular invasion.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Muto M, Yao K, Kaise M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig Endosc. 2016;28:379–93.CrossRefPubMed Muto M, Yao K, Kaise M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig Endosc. 2016;28:379–93.CrossRefPubMed
2.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRef
3.
Zurück zum Zitat Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefPubMed Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.CrossRefPubMed
4.
Zurück zum Zitat Ito H, Gotoda T, Oyama T, et al. Long-term oncological outcomes of submucosal manipulation during non-curative endoscopic submucosal dissection for submucosal invasive gastric cancer: a multicenter retrospective study in Japan. Surg Endosc. 2018;32:196–203.CrossRefPubMed Ito H, Gotoda T, Oyama T, et al. Long-term oncological outcomes of submucosal manipulation during non-curative endoscopic submucosal dissection for submucosal invasive gastric cancer: a multicenter retrospective study in Japan. Surg Endosc. 2018;32:196–203.CrossRefPubMed
5.
Zurück zum Zitat Hoteya S, Iizuka T, Kikuchi D, et al. Clinicopathological outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Digestion. 2016;93:53–8.CrossRefPubMed Hoteya S, Iizuka T, Kikuchi D, et al. Clinicopathological outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Digestion. 2016;93:53–8.CrossRefPubMed
6.
Zurück zum Zitat Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef
7.
Zurück zum Zitat Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein–Barr virus positivity: an international pooled analysis. Gut. 2014;63:236–43.CrossRefPubMed Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein–Barr virus positivity: an international pooled analysis. Gut. 2014;63:236–43.CrossRefPubMed
8.
Zurück zum Zitat Liu X, Liu J, Qiu H, et al. Prognostic significance of Epstein–Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15:782.CrossRefPubMedPubMedCentral Liu X, Liu J, Qiu H, et al. Prognostic significance of Epstein–Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15:782.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat van Beek J, zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22:664–70.CrossRefPubMed van Beek J, zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22:664–70.CrossRefPubMed
10.
Zurück zum Zitat Tokunaga M, Land CE. Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Cancer Epidemiol Biomark Prev. 1998;7:449–50. Tokunaga M, Land CE. Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Cancer Epidemiol Biomark Prev. 1998;7:449–50.
11.
Zurück zum Zitat Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008;99:1726–33.CrossRefPubMed Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008;99:1726–33.CrossRefPubMed
12.
Zurück zum Zitat Park JH, Kim EK, Kim YH, et al. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer. Gastric Cancer. 2016;19:1041–51.CrossRefPubMed Park JH, Kim EK, Kim YH, et al. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer. Gastric Cancer. 2016;19:1041–51.CrossRefPubMed
13.
Zurück zum Zitat Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3–43.CrossRef Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3–43.CrossRef
14.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
15.
Zurück zum Zitat Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan. 1968;59:251–8.PubMed Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan. 1968;59:251–8.PubMed
16.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC press; 2010. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC press; 2010.
17.
Zurück zum Zitat Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed
18.
Zurück zum Zitat Uemura Y, Tokunaga M, Arikawa J, et al. A unique morphology of Epstein-Barr virus-related early gastric carcinoma. Cancer Epidemiol Biomarkers Prev. 1994;3:607–11.PubMed Uemura Y, Tokunaga M, Arikawa J, et al. A unique morphology of Epstein-Barr virus-related early gastric carcinoma. Cancer Epidemiol Biomarkers Prev. 1994;3:607–11.PubMed
19.
Zurück zum Zitat Burke AP, Yen TS, Shekitka KM, et al. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 1990;3:377–80.PubMed Burke AP, Yen TS, Shekitka KM, et al. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 1990;3:377–80.PubMed
20.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRef Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRef
21.
Zurück zum Zitat Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137:824–33.CrossRefPubMedPubMedCentral Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137:824–33.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Akiba S, Koriyama C, Herrera-Goepfert R, et al. Epstein-Barr virus associated gastric carcinoma: Epidemiological and clinicopathological features. Cancer Sci. 2008;99:195–201.CrossRefPubMed Akiba S, Koriyama C, Herrera-Goepfert R, et al. Epstein-Barr virus associated gastric carcinoma: Epidemiological and clinicopathological features. Cancer Sci. 2008;99:195–201.CrossRefPubMed
23.
Zurück zum Zitat Koriyama C, Akiba S, Minakami Y, et al. Environmental factors related to Epstein-Barr virus-associated gastric cancer in Japan. J Exp Clin Cancer Res. 2005;24:547–53.PubMed Koriyama C, Akiba S, Minakami Y, et al. Environmental factors related to Epstein-Barr virus-associated gastric cancer in Japan. J Exp Clin Cancer Res. 2005;24:547–53.PubMed
24.
Zurück zum Zitat Arikawa J, Tokunaga M, Satoh E, et al. Morphological characteristics of Epstein-Barr virus-related early gastric carcinoma: a case-control study. Pathol Int. 1997;47:360–7.CrossRefPubMed Arikawa J, Tokunaga M, Satoh E, et al. Morphological characteristics of Epstein-Barr virus-related early gastric carcinoma: a case-control study. Pathol Int. 1997;47:360–7.CrossRefPubMed
25.
Zurück zum Zitat Nishikawa J, Iizasa H, Yoshiyama H, et al. Clinical importance of Epstein-Barr virus-associated gastric cancer. Cancers. 2018;10:E167.CrossRefPubMed Nishikawa J, Iizasa H, Yoshiyama H, et al. Clinical importance of Epstein-Barr virus-associated gastric cancer. Cancers. 2018;10:E167.CrossRefPubMed
26.
Zurück zum Zitat Lim H, Park YS, Lee JH, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus. Clin Gastroenterol Hepatol. 2015;13:1738–44.CrossRefPubMed Lim H, Park YS, Lee JH, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus. Clin Gastroenterol Hepatol. 2015;13:1738–44.CrossRefPubMed
27.
Zurück zum Zitat Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer. 1976;38:232–43.CrossRefPubMed Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer. 1976;38:232–43.CrossRefPubMed
28.
Zurück zum Zitat Nakamura S, Ueki T, Yao T, et al. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer. 1994;73:2239–49.CrossRefPubMed Nakamura S, Ueki T, Yao T, et al. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer. 1994;73:2239–49.CrossRefPubMed
29.
Zurück zum Zitat Yanai H, Nishikawa J, Mizugaki Y, et al. Endoscopic and pathologic features of Epstein–Barr virus-associated gastric carcinoma. Gastrointest Endosc. 1997;45:236–42.CrossRefPubMed Yanai H, Nishikawa J, Mizugaki Y, et al. Endoscopic and pathologic features of Epstein–Barr virus-associated gastric carcinoma. Gastrointest Endosc. 1997;45:236–42.CrossRefPubMed
Metadaten
Titel
Epstein–Barr virus status is a promising biomarker for endoscopic resection in early gastric cancer: proposal of a novel therapeutic strategy
verfasst von
Hiroki Osumi
Hiroshi Kawachi
Toshiyuki Yoshio
Satoshi Ida
Noriko Yamamoto
Yusuke Horiuchi
Akiyoshi Ishiyama
Toshiaki Hirasawa
Tomohiro Tsuchida
Naoki Hiki
Kengo Takeuchi
Junko Fujisaki
Publikationsdatum
02.03.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 9/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01562-0

Weitere Artikel der Ausgabe 9/2019

Journal of Gastroenterology 9/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.